Injected weight-loss drugs Wegovy, from Novo Nordisk, and Eli Lilly's Zepbound have U.S. list prices of over $1,000 a month.

President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move ...

The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...